Evidence map›Paper›PMID 26237066›Full record

ArticleJournal of clinical medicine2013

Engraftment Outcomes after HPC Co-Culture with Mesenchymal Stromal Cells and Osteoblasts.

Matthew M Cook, Michael R Doran, Katarina Kollar, Valerie Barbier, Ingrid G Winkler, Jean-Pierre Levesque, Gary Brooke, Kerry Atkinson

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Matthew M CookStem Cell and Regenerative Medicine Group, Biological Therapies Program, Mater Research Institute, University of Queensland, TRI Building, 37 Kent Street, Woolloongabba, Queensland 4102, Australia. mattmaccook@gmail.com.
Michael R DoranStem Cell and Regenerative Medicine Group, Biological Therapies Program, Mater Research Institute, University of Queensland, TRI Building, 37 Kent Street, Woolloongabba, Queensland 4102, Australia. michael.doran@qut.edu.au.
Katarina KollarStem Cell and Regenerative Medicine Group, Biological Therapies Program, Mater Research Institute, University of Queensland, TRI Building, 37 Kent Street, Woolloongabba, Queensland 4102, Australia. katekollar@gmail.com.
Valerie BarbierStem Cell and Cancer Group, Biological Therapies Program, Mater Medical Research Institute, Level 3, Aubigny Place, Raymond Terrace, South Brisbane, Queensland 4101, Australia. vbarbier@mmri.mater.org.au.
Ingrid G WinklerStem Cell and Cancer Group, Biological Therapies Program, Mater Medical Research Institute, Level 3, Aubigny Place, Raymond Terrace, South Brisbane, Queensland 4101, Australia. iwinkler@mmri.mater.org.au.
Jean-Pierre LevesqueSchool of Medicine, University of Queensland, 288 Herston Road, Herston, Queensland 4006, Australia. jplevesque@mmri.mater.org.au.
Gary BrookeStem Cell and Regenerative Medicine Group, Biological Therapies Program, Mater Research Institute, University of Queensland, TRI Building, 37 Kent Street, Woolloongabba, Queensland 4102, Australia. gpbrooke@gmail.com.
Kerry AtkinsonStem Cell and Regenerative Medicine Group, Biological Therapies Program, Mater Research Institute, University of Queensland, TRI Building, 37 Kent Street, Woolloongabba, Queensland 4102, Australia. m.atkinson1@uq.edu.au.
Mater Research · AUUniversity of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Haematopoietic stem cell (HSC) transplantation is an established cell-based therapy for a number of haematological diseases. To enhance this therapy, there is considerable interest in expanding HSCs in artificial niches prior to transplantation. This study compared murine HSC expansion supported through co-culture on monolayers of either undifferentiated mesenchymal stromal cells (MSCs) or osteoblasts. Sorted Lineage(-) Sca-1(+) c-kit(+) (LSK) haematopoietic stem/progenitor cells (HPC) demonstrated proliferative capacity on both stromal monolayers with the greatest expansion of LSK shown in cultures supported by osteoblast monolayers. After transplantation, both types of bulk-expanded cultures were capable of engrafting and repopulating lethally irradiated primary and secondary murine recipients. LSKs co-cultured on MSCs showed comparable, but not superior, reconstitution ability to that of freshly isolated LSKs. Surprisingly, however, osteoblast co-cultured LSKs showed significantly poorer haematopoietic reconstitution compared to LSKs co-cultured on MSCs, likely due to a delay in short-term reconstitution. We demonstrated that stromal monolayers can be used to maintain, but not expand, functional HSCs without a need for additional haematopoietic growth factors. We also demonstrated that despite apparently superior in vitro performance, co-injection of bulk cultures of osteoblasts and LSKs in vivo was detrimental to recipient survival and should be avoided in translation to clinical practice.

Indexed as

ex vivo expansionhaematopoietic reconstitutionhaematopoietic stem cellsmesenchymal stromal cellsosteoblasts

Identifiers

PMID26237066
PMCPMC4470232
OpenAlexW2088686745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.